• 1
    Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:31524.
  • 2
    Gorman CL, Cope AP. Immune-mediated pathways in chronic inflammatory arthritis. Best Pract Res Clin Rheumatol 2008; 22:22138.
  • 3
    Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223:719.
  • 4
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:227585.
  • 5
    Furst DE, Keystone EC, Kirkham B et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67 (Suppl. 3):iii225.
  • 6
    Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease–disintegrin proteins (ADAMs). Curr Top Dev Biol 2003; 54:10123.
  • 7
    Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17:730.
  • 8
    Kheradmand F, Werb Z. Shedding light on sheddases: role in growth and development. Bioessays 2002; 24:812.
  • 9
    Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2009; 29:25889.
  • 10
    Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics 1997; 41:5662.
  • 11
    Gomez-Gaviro M, Dominguez-Luis M, Canchado J et al. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 2007; 178:805363.
  • 12
    Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19:28995.
  • 13
    Mandelin J, Li TF, Hukkanen MV et al. Increased expression of a novel osteoclast-stimulating factor, ADAM8, in interface tissue around loosened hip prostheses. J Rheumatol 2003; 30:20338.
  • 14
    Ainola M, Li TF, Mandelin J et al. Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction. Ann Rheum Dis 2009; 68:42734.
  • 15
    Amour A, Knight CG, English WR et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002; 524:1548.
  • 16
    Hall T, Leone JW, Wiese JF et al. Autoactivation of human ADAM8: a novel pre-processing step is required for catalytic activity. Biosci Rep 2008.
  • 17
    Schlomann U, Wildeboer D, Webster A et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002; 277:4821019.
  • 18
    Roach ML, Stock JL, Byrum R, Koller BH, McNeish JD. A new embryonic stem cell line from DBA/1lacJ mice allows genetic modification in a murine model of human inflammation. Exp Cell Res 1995; 221:5205.
  • 19
    Stanley ER. Murine bone marrow-derived macrophages. Methods Mol Biol 1997; 75:3014.
  • 20
    Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981; 154:688700.
  • 21
    Bendele AM, Chlipala ES, Scherrer J et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43:264859.
  • 22
    Roark CL, French JD, Taylor MA, Bendele AM, Born WK, O'Brien RL. Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells. J Immunol 2007; 179:557683.
  • 23
    Beare A, Stockinger H, Zola H, Nicholson I. Monoclonal antibodies to human cell surface antigens. Curr Protoc Immunol 2008; Appendix 4:4A.
  • 24
    Nadel JA. Biology of mast cell tryptase and chymase. Ann NY Acad Sci 1991; 629:31931.
  • 25
    Paul WE. Fundamental immunology. Philadelphia, PA: Lippincott-Raven, 1999:105166.
  • 26
    Moss ML, Rasmussen FH. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 2007; 366:1448.
  • 27
    Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98:6218.
  • 28
    Kelly K, Hutchinson G, Nebenius-Oosthuizen D et al. ADAM8: expression analysis and targeted deletion in mice. Dev Dyn 2005; 232:22131.
  • 29
    Hill RJ, Dabbagh K, Phippard D et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008; 327:61019.
  • 30
    Ibrahim SM, Yu X. Dissecting the genetic basis of rheumatoid arthritis in mouse models. Curr Pharm Des 2006; 12:37539.
  • 31
    Caccese RG, Zimmerman JL, Carlson RP. Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice. Mediators Inflamm 1992; 1:2739.
  • 32
    Joosten LA, Helsen MM, Van De Loo FA, Van Den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39:797809.
  • 33
    Choi SJ, Han JH, Roodman GD. ADAM8: a novel osteoclast stimulating factor. J Bone Miner Res 2001; 16:81422.
  • 34
    Rao H, Lu G, Kajiya H et al. a novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res 2006; 21:165765.
  • 35
    Naus S, Reipschlager S, Wildeboer D et al. Identification of candidate substrates for ectodomain shedding by the metalloprotease–disintegrin ADAM8. Biol Chem 2006; 387:33746.
  • 36
    Xanthoulea S, Pasparakis M, Kousteni S et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004; 200:36776.
  • 37
    Mihara K, Almansa C, Smeets RL et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha. Br J Pharmacol 2008; 154:15364.